[Tyrosine kinase inhibitor as a targeted therapy for GIST tumors].
Joensuu
Heikki
H
HYKS:n syöpätautien klinikka PL 180, 00029 HUS. heikki.joensuu@hus.fi
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D007890:Leiomyosarcoma / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit